Ultragenyx Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Update
Portfolio Pulse from
Ultragenyx reported its financial results for Q4 and the full year 2024, with total revenue of $560 million, surpassing guidance. Key products Crysvita® and Dojolvi® contributed $410 million and $88 million, respectively.
February 13, 2025 | 9:15 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Ultragenyx's 2024 financial results exceeded expectations with $560 million in total revenue. Crysvita® and Dojolvi® were major contributors, indicating strong product performance.
Ultragenyx's reported revenue of $560 million for 2024 exceeded its guidance, driven by strong sales of Crysvita® and Dojolvi®. This positive financial performance is likely to boost investor confidence and positively impact the stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100